Living in ignorance of trial results
Thousands of patients who took place in clinical trials may never learn whether the drugs or devices were faulty, the New York Times says. Although the US Congress recently required manufacturers to disclose results of approved products, it did not require disclosure of non-approved products. Hence, people with implanted medical devices such as shunts or breast implants could be at risk.
For everyone involved in the research, “there is a tremendous incentive to go on, to forget about the old and move on to the new,” said Drummond Rennie, a deputy editor at the Journal of the American Medical Association.
Although researchers conducting clinical studies are not required to disclose test results to participants, they are supposed to alert them to emerging product dangers. They are also supposed to follow the health of participants. But this often is neglected.
Industry successfully lobbied Congress against disclosure of the results of trials which failed. The manufacturers argued that releasing data about them would confuse patients and would give away valuable information to competitors about devices under development that might succeed later on.
- How long can you put off seeing the doctor because of lockdowns? - December 3, 2021
- House of Lords debates assisted suicide—again - October 28, 2021
- Spanish government tries to restrict conscientious objection - October 28, 2021
More Stories
Mortality rates for American kids are rising for the first time in 50 years
US President Joe Biden is so concerned about the future of American children that he inserted a mandate for affordable...
Will Pope Francis be composted?
Will Pope Francis be composted instead of buried in St Peter’s Basilica in Rome with his predecessors? It’s unlikely. But...
The virtues and the vices of the outrageous
A Norwegian bioethicist, Anna Smajdor, recently set out a case for “Whole Body Gestational Donation” – using the wombs of...
More than 200 people have been treated with experimental CRISPR therapies
Scientists believe that CRISPR gene editing technologies will transform medicine. But how many people have been treated so far? According...
Asia-Pacific IVF market could reach US$46 billion by 2031
According to a market survey by Allied Market Research, IVF is booming in the Asia-Pacific region. The market size was...
Third global summit on human genome editing: Moving on after the He experiment
The much anticipated Third International Summit on Human Genome Editing was held in London earlier this month to explore the...